Nanocarriers for transmucosal vaccine delivery

Current Nanoscience

Volumn 7, Issue 2, 2011, Pages 160-177

  Jain, Sanyog ^a   Khomane, Kailas ^a   Jain, Amit K ^a   Dani, Prateek ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Mucosal immunity; Mucosal vaccination; Nanocarriers; Nanoparticles; Novel drug delivery systems; Vaccine delivery

Indexed keywords

MUCOSAL IMMUNITY; MUCOSAL VACCINATION; NANOCARRIERS; NOVEL DRUG DELIVERY SYSTEMS; VACCINE DELIVERY;

ANTIGENS; BIOCHEMISTRY; DRUG DELIVERY; NANOPARTICLES;

VACCINES;

ANTIGEN; BILOSOME; BOVINE SERUM ALBUMIN; CARBON NANOTUBE; CHITOSAN; DENDRIMER; DRUG ADDITIVE; DRUG CARRIER; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; LIPOSOME; NANOCARRIER; NIOSOME; POLYGLACTIN; POLYMER; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG; VACCINE; VIROSOME;

ANTIBODY TITER; ANTIGEN PRESENTATION; ARTICLE; BRONCHUS ASSOCIATED LYMPHOID TISSUE; CELL TRANSPORT; CELLULAR IMMUNITY; DESENSITIZATION; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG TARGETING; DRUG TRANSFORMATION; DRUG TREATMENT FAILURE; GLASS TRANSITION TEMPERATURE; HUMAN; HUMORAL IMMUNITY; HYDROPHILICITY; HYDROPHOBICITY; IMMUNE RESPONSE; INTESTINE LYMPHATIC TISSUE; LYMPHOID TISSUE; MICELLE; MUCOSAL ADMINISTRATION; NANOEMULSION; NANOENCAPSULATION; NASAL ASSOCIATED LYMPHOID TISSUE; NONHUMAN; PARTICLE SIZE; PEYER PATCH; PRIORITY JOURNAL; PULMONARY ROUTE; SUBCONJUNCTIVAL DRUG ADMINISTRATION; VACCINATION;

EID: 79951702169     PISSN: 15734137     EISSN: None     Source Type: Journal    
DOI: 10.2174/157341311794653541     Document Type: Article

References (192)

1. Holmgren, J.; Czerkinsky, C.; Eriksson, K.; Mharandi, A. Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine 2003, 21, 89-95.
2. Davis, S.; Nasal vaccines. Adv. Drug Deliv. Rev. 2001, 51, 21-42.
3. Vyas, S. P.; Gupta, P. N. Implication of nanoparticles/microparticles in mucosal vaccine delivery. Expert Rev. Vaccines 2007, 6(3), 401-418.
4. Van der Lubben, I. M.; Verhoef, J. C.; Borchard, G.; Junginger, H. E. Chitosan for mucosal vaccination. Adv. Drug Deliv. Rev. 2001, 52(2), 139-144.
5. Mestecky, J.; Michalek, S. M.; Moldoveanu, Z.; Russell, M. W;. Routes of immunization and antigen delivery systems for optimal mucosal immune responses in humans. Behring Inst. Mitt. 1997, 98, 33-43.
6. Neutra, M. R.; Kozlowski, P. A.; Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. 2006, 6(2), 148-158.
7. Hobson, P.; Barnfield, C.; Barnes, A.; Klavinskis, L. S. Mucosal immunization with DNA vaccines. Methods 2003, 31(3), 217-224.
8. Czerkinsky, C.; Anjuere, F.; McGhee, J. R.; George-Chandy, A.; Holmgren, J.; Kieny, M. P.; Fujiyashi, K.; Mestecky, J. F.; Pierrefite-Carle, V.; Rask, C.; Mucosal immunity and tolerance: relevance to vaccine development. Immunol. Rev. 1999, 170, 197-222.
9. Borges, O.; Lebre, F.; Bento, D.; Borchard, G.; Junginger, H. E.; Mucosal vaccines: recent progress in understanding the natural barriers. Pharm. Res. 2010, 27(2), 211-223.
10. Sminia, T.; Kraal, G. Nasal-associated lymphoid tissue. In Mucosal Immunology, Mestecky, J.; Bienenstock, J. Eds. Elsevier Academic Press: San Diego, 1999; Vol. 2, pp 357-364.
11. McGhee, J. R.; Mestecky, J.; Dertzbaugh, M. T.; Eldridge, J. H.; Hirasawa, M.; Kiyono, H. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 1992, 10(2), 75-88.
12. Partidos, C. D. Intranasal vaccines: forthcoming challenges. Pharm. Sci. Technol. Today 2000, 3(8), 273-281.
13. Czerkinsky, C.; Mucosal immunity and tolerance: relevance to vaccine development. Immunol. Rev. 1999, 170(1), 197-222.
14. Kuper, C. F.; Koornstra, P. J.; Hameleers, D. M.; Biewenga, J.; Spit, B. J.; Duijvestijn, A. M.; Van Breda, V. P. J.; Sminia, T.; The role of nasopharyngeal lymphoid tissue. Immunol. Today 1992, 13(6), 219-224.
15. Ugwoke, M. I.; Verbeke, N.; Kinget, R. The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J. Pharm. Pharmacol. 2001, 53, (1), 3-22.
16. Csaba, N.; Garcia-Fuentes, M.; Alonso, M. J.; Nanoparticles for nasal vaccination. Adv. Drug Deliv. Rev. 2009, 61(2), 140-157.
17. Jahnsen, F. L.; Gran, E.; Haye, R.; Brandtzaeg, P. Human nasal mucosa contains antigen-presenting cells of strikingly different functional phenol types. Am. J. Respir. Cell Mol. Biol. 2004, 30(1), 31-37.
18. Yanagita, M.; Hiroi, T.; Kitagaki, N.; Hamada, S.; Ito, H.; Shimauchi, H.; Murakami, S.; Okada, H.; Kiyono, H. Nasopharyngeal-associated lympho reticular tissue immunity: fimbriae-specific Th1 and Th2 cell-regulated IgA responses for the inhibition of bacterial attachment to epithelial cells and subsequent inflammatory cytokine production 1. J. Immunol. 1999, 162(6), 3559-3565.
19. Wu, H. Y.; Russell, M. W.; Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system. Immunol. Res. 1997, 16(2), 187-201.
20. Moore, A.; McGuirk, P.; Adams, S.; Jones, W. C.; Paul McGee, J.; O'Hagan, D. T.; Mills, K. H. G. Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells. Vaccine 1995, 13(18), 1741-1749.
21. Olaguibel, J. M.; Alvarez Puebla, M. J. Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta analysis. J. Investig. Allergol. Clin. Immunol. 2005, 15(1), 9-16.
22. Van Overtvelt, L.; Razafindratsita, A.; St-Lu, N.; Didierlaurent, A.; Batard, T.; Lombardi, V.; Martin, E.; Moingeon, P.; Sublingual vaccines based on wild-type recombinant allergens. Allerg. Immunol. 2006, 38(7), 247-249.
23. Amorij, J. P.; Saluja, V.; Petersen, A. H.; Hinrichs, W. L. J.; Huckriede, A.; Frijlink, H. W. Pulmonary delivery of an inulin-stabilized influenza subunit vaccine prepared by spray-freeze drying induces systemic, mucosal humoral as well as cell-mediated immune responses in BALB/c mice. Vaccine 2007, 25(52), 8707-8717.
24. Di Tommaso, A.; Saletti, G.; Pizza, M.; Rappuoli, R.; Dougan, G.; Abrignani, S.; Douce, G.; De Magistris, M. T.; Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect. Immun. 1996, 64(3), 974-979.
25. Nesburn, A. B.; Bettahi, I.; Zhang, X.; Zhu, X.; Chamberlain, W.; Afifi, R. E.; Wechsler, S. L.; BenMohamed, L. Topical/mucosal delivery of sub-unit vaccines that stimulate the ocular mucosal immune system. Ocul. Surf. 2006, 4(4), 178-187.
26. Seo, K. Y.; Han, S. J.; Cha, H. R.; Seo, S. U.; Song, J. H.; Chung, S. H.; Kweon, M. N. Eye mucosa: an efficient vaccine delivery route for inducing protective immunity. J. Immunol. 2010, 185(6), 3610-3619.
27. Singh, A.; Misra, R.; Mohanty, C.; Sahoo, S. K. Applications of nanotech nology in vaccine delivery. Int. J. Green Nanotechnol. Biomed. 2010, 2(1), 25-45.
28. Farokhzad, O. C.; Langer, R. Impact of nanotechnology on drug delivery. ACS Nano 2009, 3(1), 16-20.
29. Shahiwala, A.; Vyas, T. K.; Amiji, M. M.; Nanocarriers for systemic and mucosal vaccine delivery. Recent Pat. Drug Deliv. Formul. 2007, 1, 1-9.
30. Griffiths, G. D.; Bailey, S. C.; Hambrook, J. L.; Keyte, M.; Jayasekera, P.; Miles, J.; Williamson, E. Liposomally-encapsulated ricin toxoid vaccine delivered intratracheally elicits a good immune response and protects against a lethal pulmonary dose of ricin toxin. Vaccine 1997, 15(17-18), 1933-1939.
31. Arbos, P.; Campanero, M. A.; Arangoa, M. A.; Irache, J. M. Nanoparticles with specific bioadhesive properties to circumvent the pre-systemic degradation of fluorinated pyrimidines. J. Control Release 2004, 96(1), 55-65.
32. Jani, P. U.; McCarthy, D. E.; Florence, A. T. Nanosphere and microsphere uptake via Peyer's patches: observation of the rate of uptake in the rat after a single oral dose. Int. J. Pharm. 1992, 86(2-3), 239-246.
33. Florence, A. T. Nanoparticle uptake by the oral route: Fulfilling its potential? Drug Discov. Today:Technol. 2005, 2(1), 75-81.
34. Florence, A. T.; Hussain, N. Transcytosis of nanoparticle and dendrimer delivery systems: evolving vistas. Adv. Drug Deliv. Rev. 2001, 50, 69-89.
35. Jani, P.; Halbert, G. W.; Langridge, J.; Florence, A. T. Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J. Pharm. Pharmacol. 1990, 42(12), 821-826.
36. Uchida, T.; Martin, S.; Foster, T. P.; Wardley, R. C.; Grimm, S. Dose and load studies for subcutaneous and oral delivery of poly (lactide-co-glycolide) microspheres containing ovalbumin. Pharm. Res. 1994, 11(7), 1009-1015.
37. Jung, T.; Kamm, W.; Breitenbach, A.; Kaiserling, E.; Xiao, J. X.; Kissel, T. Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? Eur. J. Pharm. Biopharm. 2000, 50(1), 147-160.
38. Kreuter, J.; Liehl, E.; Berg, U.; Soliva, M.; Speiser, P. P. Influence of hydro phobicity on the adjuvant effect of particulate polymeric adjuvants. Vaccine 1988, 6(3), 253-6.
39. Calvo, P.; Remunan-Lopez, C.; Vila-Jato, J. L.; Alonso, M. J. Novel hydro philic chitosan-polyethylene oxide nanoparticles as protein carriers. J. Appl. Polym. Sci. Symp. 1997, 63(1), 125-132.
40. Fernandez-Urrusuno, R.; Calvo, P.; Remunan-Lopez, C.; Vila-Jato, J. L.;Jose Alonso, M. Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm. Res. 1999, 16(10), 1576-1581.
41. Csaba, N.; Garcia-Fuentes, M.; Alonso, M. J. The performance of nanocarriers for transmucosal drug delivery. Expert Opin. Drug Deliv. 2006, 3(4), 463-478.
42. Jani, P.; Halbert, G. W.; Langridge, J.; Florence, A. T. Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J. Pharm. Pharmacol. 1990, 42(12), 821-826.
43. Norris, D. A.; Puri, N.; Sinko, P. J.; The effect of physical barriers and properties on the oral absorption of particulates. Adv. Drug Deliv. Rev. 1998, 34(2-3), 135-154.
44. Rajapaksa, T. E.; Lo, D. D.; Microencapsulation of vaccine antigens and adjuvants for mucosal targeting. Curr. Immunol. Rev. 2010, 6(1), 29-37.
45. Takeuchi, H.; Yamamoto, H.; Kawashima, Y. Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv. Drug Deliv. Rev. 2001, 47(1), 39-54.
46. Prego, C.; García, M.; Torres, D.; Alonso, M. J. Transmucosal macromolecular drug delivery. J. Control Release 2005, 101(1-3), 151-162.
47. Gupta, P. N.; Mahor, S.; Rawat, A.; Khatri, K.; Goyal, A.; Vyas, S. P.; Lectin anchored stabilized biodegradable nanoparticles for oral immunization 1. Development and in vitro evaluation. Int. J. Pharm. 2006, 318(1-2), 163-173.
48. Jaganathan, K. S.; Singh, P.; Prabakaran, D.; Mishra, V.; Vyas, S. P. Development of a single-dose stabilized poly (D, L-lactic-co-glycolic acid) microspheres-based vaccine against hepatitis B. J. Pharm. Pharmacol. 2004, 56(10), 1243-1250.
49. Sahoo, S. K.; Panyam, J.; Prabha, S.; Labhasetwar, V.; Residual polyvinyl alcohol associated with poly (d, l-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J. Control Release 2002, 82(1), 105-114.
50. Stuart, L. M.; Ezekowitz, R. A. B. Phagocytosis Elegant Complexity. Immunity 2005, 22(5), 539-550.
51. Calvo, P.; Remunan-Lopez, C.; Vila-Jato, J. L.; Alonso, M. J. Development of positively charged colloidal drug carriers: chitosan-coated polyester nano- capsules and submicron-emulsions. Colloid Polym. Sci. 1997, 275(1), 46-53.
52. Ilium, L.; Chitosan and its use as a pharmaceutical excipient. Pharm. Res. 1998, 15(9), 1326-1331.
53. Lueben, H. L.; de Leeuw, B. J.; Langemeÿer, M. W. E.; de Boer, A. B. G.; Verhoef, J. C.; Junginger, H. E.; Mucoadhesive polymers in peroral peptide drug delivery. VI. carbomer and chitosan improve the intestinal absorption of the peptide drug buserelin in vivo. Pharm. Res. 1996, 13(11), 1668-1672.
54. Van der Lubben, I. M.; Verhoef, J. C.; van Aelst, A. C.; Borchard, G.; Junginger, H. E. Chitosan microparticles for oral vaccination: preparation, characterization and preliminary in vivo uptake studies in murine Peyer's patches. Biomaterials 2001, 22(7), 687-694.
55. Janes, K. A.; Calvo, P.; Alonso, M. J. Polysaccharide colloidal particles as delivery systems for macromolecules. Adv. Drug Deliv. Rev. 2001, 47(1), 83-97.
56. Thanou, M.; Verhoef, J. C.; Junginger, H. E.; Chitosan and its derivatives as intestinal absorption enhancers. Adv. Drug Deliv. Rev. 2001, 50, 91-101.
57. van der Lubben, I. M.; Verhoef, J. C.; Borchard, G.; Junginger, H. E. Chitosan for mucosal vaccination. Adv. Drug Deliv. Rev. 2001, 52(2), 139-144.
58. Hejazi, R.; Amiji, M. Chitosan-based gastrointestinal delivery systems. J. Control Release 2003, 89(2), 151-165.
59. Vila, A.; Sánchez, A.; Tobió, M.; Calvo, P.; Alonso, M. J. Design of biode gradable particles for protein delivery. J. Control Release 2002, 78(1-3), 15-24.
60. Hejazi, R.; Amiji, M. Stomach-specific anti-H. pylori therapy. I: preparation and characterization of tetracyline-loaded chitosan microspheres. Int. J. Pharm. 2002, 235(1-2), 87-94.
61. Jain, S.; Sharma, R. K.; Vyas, S. P. Chitosan nanoparticles encapsulated vesicular systems for oral immunization: preparation, in-vitro and in-vivo characterization. J. Pharm. Pharmacol. 2006, 58(3), 303-310.
62. Borges, O.; Cordeiro-da-Silva, A.; Romeijn, S. G.; Amidi, M.; de Sousa, A.; Borchard, G.; Junginger, H. E.; Uptake studies in rat Peyer's patches, cytotoxicity and release studies of alginate coated chitosan nanoparticles for mucosal vaccination. J. Control Release 2006, 114(3), 348-358.
63. Seferian, P. G.; Martinez, M. L. Immune stimulating activity of two new chitosan containing adjuvant formulations. Vaccine 2000, 19(6), 661-668.
64. Roy, K.; Mao, H. Q.; Huang, S. K.; Leong, K. W. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat. Med. 1999, 5(4), 387.
65. Iqbal, M.; Lin, W.; Jabbal-Gill, I.; Davis, S. S.; Steward, M. W.; Illum, L. Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL responses in BALB/c mice. Vaccine 2003, 21(13-14), 1478-1485.
66. Bivas-Benita, M.; van Meijgaarden, K. E.; Franken, K.; Junginger, H. E.; Borchard, G.; Ottenhoff, T. H. M.; Geluk, A. Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A* 0201-restricted T-cell epitopes of Mycobacterium tuberculosis. Vaccine 2004, 22(13-14), 1609-1615.
67. Vila, A.; Sanchez, A.; Janes, K.; Behrens, I.; Kissel, T.; Jato, J. L. V.; Alonso, M. J. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur. J. Pharm. Biopharm. 2004, 57(1), 123-131.
68. Nagamoto, T.; Hattori, Y.; Takayama, K.; Maitani, Y.; Novel Chitosan particles and chitosan-coated emulsions inducing immune response via intranasal vaccine delivery. Pharm. Res. 2004, 21(4), 671-674.
69. Xu, W.; Shen, Y.; Jiang, Z.; Wang, Y.; Chu, Y.; Xiong, S. Intranasal delivery of chitosan-DNA vaccine generates mucosal SIgA and anti-CVB3 protection. Vaccine 2004, 22(27-28), 3603-3612.
70. Wei, K. Fan, M. Wu, B. Preliminary study of glucan-binding protein B chitosan nanoparticles as a novel nasal delivery system for anti-carious vaccine. Kouqiang Yixue Yanjiu 2005, 21, 488-491.
71. Rezaei, M. A.; Preparation and evaluation of chitosan nanoparticles containing diphtheria toxoid as new carriers for nasal vaccine delivery in mice. Arch. Razi Inst. 2006, 61, 13-25.
72. Kim, B. G. Kang, I. J.; Chitosan nanoparticles for the effective vaccine delivery system In NSTI Nanotechnology Conference and Trade Show, Boston, MA, United States, May 7-11. 2006; Vol. 2, pp 388-391
73. Amidi, M.; Romeijn, S. G.; Verhoef, J. C.; Junginger, H. E.; Bungener, L.; Huckriede, A.; Crommelin, D. J. A.; Jiskoot, W. N-Trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: Biological properties and immunogenicity in a mouse model. Vaccine 2007, 25(1), 144-153.
74. Sayin, B.; Somavarapu, S.; Li, X. W.; Thanou, M.; Sesardic, D.; Alpar, H. O.; Senel, S.; Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery. Int. J. Pharm. 2008, 363(1-2), 139-148.
75. Borges, O.; Cordeiro-da-Silva, A.; Tavares, J.; Santarém, N.; de Sousa, A.; Borchard, G.; Junginger, H. E.; Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles. Eur. J. Pharm. Biopharm. 2008, 69(2), 405-416.
76. Rajesh Kumar, S.; Ishaq Ahmed, V. P.; Parameswaran, V.; Sudhakaran, R.; Sarath Babu, V.; Sahul Hameed, A. S. Potential use of chitosan nanoparticles for oral delivery of DNA vaccine in Asian sea bass (Lates calcarifer) to protect from Vibrio (Listonella) anguillarum. Fish Shellfish Immunol. 2008, 25(1-2), 47-56.
77. Khatri, K.; Goyal, A. K.; Gupta, P. N.; Mishra, N.; Vyas, S. P. Plasmid DNA loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B. Int. J. Pharm. 2008, 354(1-2), 235-241.
78. Li, X. Y.; Li, X.; Kong, X. Y.; Shi, S.; Guo, G.; Zhang, J.; Luo, F.; Zhao, X.; Wei, Y. Q.; Qian, Z. Y. Preparation of N-trimethyl chitosan-protein nanoparticles intended for vaccine delivery. J. Nanosci. Nanotechnol. 2010, 10(8), 4850-4858.
79. Alonso, M. J.; Gupta, R. K.; Min, C.; Siber, G. R.; Langer, R. Biodegradable microspheres as controlled-release tetanus toxoid delivery systems. Vaccine 1994, 12(4), 299-306.
80. Thomasin, C.; Corradin, G.; Men, Y.; Merkle, H. P.; Gander, B. Tetanus toxoid and synthetic malaria antigen containing poly (lactide)/poly (lactide-co-glycolide) microspheres: importance of polymer degradation and antigen release for immune response. J. Control Release 1996, 41(1-2), 131-145.
81. Gupta, P. N.; Khatri, K.; Goyal, A. K.; Mishra, N.; Vyas, S. P. M-cell tar-geted biodegradable PLGA nanoparticles for oral immunization against hepatitis B. J. Drug Target. 2007, 15(10), 701-713.
82. Jabbal-Gill, I.; Lin, W.; Kistner, O.; Davis, S. S.; Illum, L. Polymeric lamellar substrate particles for intranasal vaccination. Adv. Drug Deliv. Rev. 2001, 51(1-3), 97-111.
83. Lemoine, D.; Deschuyteneer, M.; Hogge, F.; Préat, V.; Intranasal immunization against influenza virus using polymeric particles. J. Biomater. Sci. Polym. Ed. 1999, 10(8), 805-825.
84. Vila, A.; Sanchez, A.; Perez, C.; Alonso, M. J. PLA-PEG nanospheres: new carriers for transmucosal delivery of proteins and plasmid DNA. Polym. Adv. Tech. 2002, 13(10/12), 851-858.
85. Csaba, N.; Sánchez, A.; Alonso, M. J. PLGA: Poloxamer and PLGA: Poloxamine blend nanostructures as carriers for nasal gene delivery. J. Control. Release 2006, 113(2), 164-172.
86. Stanley, A. C.; Buxton, D.; Innes, E. A.; Huntley, J. F. Intranasal immunisation with Toxoplasma gondii tachyzoite antigen encapsulated into PLG microspheres induces humoral and cell-mediated immunity in sheep. Vaccine 2004, 22(29-30), 3929-3941.
87. Singh, J.; Pandit, S.; Bramwell, V. W.; Alpar, H. O. Diphtheria toxoid loaded poly-(e-caprolactone) nanoparticles as mucosal vaccine delivery systems. Methods 2006, 38(2), 96-105.
88. Marazuela, E. G.; Prado, N.; Moro, E.; Fernandez-Garcia, H.; Villalba, M.; Rodriguez, R.; Batanero, E. Intranasal vaccination with poly (lactide-co glycolide) microparticles containing a peptide T of Ole e 1 prevents mice against sensitization. Clin. Expe. Allergy 2008, 38(3), 520-528.
89. Liman, M.; Peiser, L.; Zimmer, G.; Pröpsting, M.; Naim, H. Y.; Rautenschlein, S. A genetically engineered prime-boost vaccination strategy for oculonasal delivery with poly (d, l-lactic-co-glycolic acid) microparticles against infection of turkeys with avian Metapneumovirus. Vaccine 2007, 25(46), 7914-7926.
90. Kofler, N.; Ruedl, C.; Rieser, C.; Wick, G.; Wolf, H. Oral immunization with poly-(D, L-lactide-co-glycolide) and poly-(L-lactic acid) microspheres containing pneumotropic bacterial antigens. Int. Arch. Allergy Immunol. 1997, 113(4), 424-31.
91. Yan, C.; Rill, W. L.; Malli, R.; Hewetson, J.; Naseem, H.; Tammariello, R.; Kende, M. Intranasal stimulation of long-lasting immunity against aerosol ricin challenge with ricin toxoid vaccine encapsulated in polymeric microspheres. Vaccine 1996, 14(11), 1031-1038.
92. Jaganathan, K. S.; Vyas, S. P.; Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant Hepatitis B antigen administered intranasally. Vaccine 2006, 24(19), 4201-4211.
93. Kuo-Haller, P.; Cu, Y.; Blum, J.; Appleton, J. A.; Saltzman, W. M. Vaccine delivery by polymeric vehicles in the mouse reproductive tract induces sustained local and systemic immunity. Mol. Pharm. 2010, 7(5), 1585-1595.
94. Bivas-Benita, M.; Lin, M. Y.; Bal, S. M.; Van Meijgaarden, K. E.; Franken, K.; Friggen, A. H.; Junginger, H. E.; Borchard, G.; Klein, M. R.; Ottenhoff, T. H. M. Pulmonary delivery of DNA encoding Mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA-PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice. Vaccine 2009, 27(30), 4010-4017.
95. Olbrich, C.; Muller, R. H.; Enzymatic degradation of SLN -effect of surfactant and surfactant mixtures. Int. J. Pharm. 1999, 180(1), 31-39.
96. [96] Almeida, A. J.; Runge, S.; Muller, R. H. Peptide-loaded solid lipid nanoparticles: influence of production parameters. Int. J. Pharm. 1997, 149(2), 255-265.
97. Rao, K. K.; Polymerized solid lipid nanoparticles for oral or mucosal delivery of therapeutic proteins and peptides. U. S. Patent Application 20070237826, Nov 10 2007.
98. Muller, R. H.; Maaben, S.; Weyhers, H.; Specht, F.; Lucks, J. S.; Cytotoxicity of magnetite-loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles. Int. J. Pharm. 1996, 138(1), 85-94.
99. Olbrich, C.; Bakowsky, U.; Lehr, C. M.; Müller, R. H.; Kneuer, C.; Cationic solid-lipid nanoparticles can efficiently bind and transfect plasmid DNA. J. Control Release 2001, 77(3), 345-355.
100. Pedersen, N.; Hansen, S.; Heydenreich, A. V.; Kristensen, H. G.; Poulsen, H. S.; Solid lipid nanoparticles can effectively bind DNA, streptavidin and bi otinylated ligands. Eur. J. Pharm. Biopharm. 2006, 62(2), 155-162.
101. Alving, C. R.; Liposomes as carriers of antigens and adjuvants. J. Immunol. Methods 1991, 140(1), 1.
102. Chikh, G.; Schutze-Redelmeir, M. P. Liposomal delivery of CTL epitopes to dendritic cells. Biosci. Rep. 2002, 22(2), 339-353.
103. Sprott, G. D.; Dicaire, C. J.; Gurnani, K.; Deschatelets, L. A.; Krishnan, L. Liposome adjuvants prepared from the total polar lipids of Haloferax volcanii, Planococcus spp. and Bacillus firmus differ in ability to elicit and sustain immune responses. Vaccine 2004, 22(17-18), 2154-2162.
104. Alving, C. R. Immunologic aspects of liposomes: presentation and processing of liposomal protein and phospholipid antigens. Rev. Biomem. 1992, 1113(3-4), 307-322.
105. Gregoriadis, G.; The immunological adjuvant and vaccine carrier properties of liposomes. J. Drug Target. 1994, 2(5), 351-356.
106. Ambrosch, F.; Wiedermann, G.; Jonas, S.; Althaus, B.; Finkel, B.; Glück, R.; Herzog, C. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 1997, 15(11), 1209-1213.
107. Tafaghodi, M.; Jaafari, M. R.; Sajadi Tabassi, S. A.; Nasal immunization studies using liposomes loaded with tetanus toxoid and CpG-ODN. Eur. J. Pharm. Biopharm. 2006, 64(2), 138-145.
108. Zhou, F.; Neutra, M. R. Antigen delivery to mucosa-associated lymphoid tissues using liposomes as a carrier. Biosci. Rep. 2002, 22(2), 355-369.
109. Zhou, F.; Kraehenbuhl, J. P.; Neutra, M. R. Mucosal IgA response to rectally administered antigen formulated in IgA-coated liposomes. Vaccine 1995, 13(7), 637-644.
110. Watarai, S.; Han, M.; Kodama, H. Antibody response in the intestinal tract of mice orally immunized with antigen associated with liposomes. J. Vet. Med. Sci. 1998, 60(9), 1047-1050.
111. Chen, H.; Torchilin, V.; Langer, R. Polymerized liposomes as potential oral vaccine carriers: stability and bioavailability. J. Control. Release 1996, 42 (3), 263-272.
112. Okada, J. Cohen, S. Langer, R.S. Polymerized liposomes with enhanced stability for oral delivery. U.S. Patent 5762904, Jun 06 1998.
113. Lasic, D. D.; Vallner, J. J.; Working, P. K.; Sterically stabilized liposomes in cancer therapy and gene delivery. Curr. Opin. Mol. Ther. 1999, 1(2), 177-85.
114. Yang, K.; Whalen, B. J.; Tirabassi, R. S.; Selin, L. K.; Levchenko, T. S.; Torchilin, V. P.; Kislauskis, E. H.; Guberski, D. L. A DNA vaccine prime followed by a liposome-encapsulated protein boost confers enhanced mucosal immune responses and protection. J. Immunol. 2008, 180(9), 6159-165.
115. Zhao, W.; Wu, W.; Xu, X. Oral vaccination with liposome-encapsulated recombinant fusion peptide of urease B epitope and cholera toxin B subunit affords prophylactic and therapeutic effects against H. pylori infection in BALB/c mice. Vaccine 2007, 25(44), 7664-7673.
116. Yasumoto, S.; Kuzuya, Y.; Yasuda, M.; Yoshimura, T.; Miyazaki, T. Oral Immunization of Common Carp with a Liposome Vaccine Fusing Koi Herpesvirus Antigen. Fish Pathol. 2006, 41(4), 141-146.
117. Yasumoto, S.; Yoshimura, T.; Miyazaki, T. Oral Immunization of Common Carp with a Liposome Vaccine Containing Aeromonas hydrophila Antigen. Fish Pathol. 2006, 41(2).
118. Klavinskis, L. S.; Gao, L.; Barnfield, C.; Lehner, T.; Parker, S. Mucosal immunization with DNA-liposome complexes. Vaccine 1997, 15(8), 818-820.
119. Childers, N. K.; Zhang, S. S.; Harokopakis, E.; Harmon, C. C.; Michalek, S. M. Properties of practical oral liposome-Streptococcus mutans glucosyltrans-ferase vaccines for effective induction of caries protection. Oral Microbiol. Immunol. 1996, 11(3), 172-180.
120. De Haan, A.; Wilschut, J. A. N. Liposomes and antiviral mucosal immunity. In Liposomes in Biomedical Applications, Pang, N. S. Ed. Harwood academic plublisher: 1995; pp 69-85.
121. Tseng, L. P.; Liang, H. J.; Deng, M. C.; Lee, K. M.; Pan, R. N.; Yang, J. C.; Huang, Y. Y.; Liu, D. Z. The influence of liposomal adjuvant on intranasal vaccination of chickens against Newcastle disease. Vet. J. 2009, 185(2), 204-210.
122. Troyer, R. M.; Propst, K. L.; Fairman, J.; Bosio, C. M.; Dow, S. W. Mucosal immunotherapy for protection from pneumonic infection with Francisella tularensis. Vaccine 2009, 27(33), 4424-4433.
123. Heurtault, B.; Gentine, P.; Thomann, J. S.; Baehr, C.; Frisch, B.; Pons, F. Design of a liposomal candidate vaccine against Pseudomonas aeruginosa and its evaluation in triggering systemic and lung mucosal immunity. Pharm. Res. 2009, 26(2), 276-285.
124. Patel, G. B.; Ponce, A.; Zhou, H.; Chen, W. Structural characterization of archaeal lipid mucosal vaccine adjuvant and delivery (AMVAD) formulations prepared by different protocols and their efficacy upon intranasal immunization of mice. J. Liposome Res. 2008, 18(2), 127-143.
125. Khatri, K.; Goyal, A. K.; Gupta, P. N.; Mishra, N.; Mehta, A.; Vyas, S. P.; Surface modified liposomes for nasal delivery of DNA vaccine. Vaccine 2008, 26(18), 2225-2233.
126. Patel, G. B.; Zhou, H.; Ponce, A.; Chen, W. Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines. Vaccine 2007, 25(51), 8622-8636.
127. Perez, O.; Lastre, M.; Cabrera, O.; del Campo, J.; Bracho, G.; Cuello, M.; Balboa, J.; Acevedo, R.; Zayas, C.; Gil, D.; New vaccines require potent adjuvants like AFPL1 and AFCo1. Scand. J. Immunol. 2007, 66(2-3), 271.
128. Tafaghodi, M.; Jaafari, M. R.; Sajadi Tabassi, S. A. Nasal immunization studies by cationic, fusogenic and cationic-fusogenic liposomes encapsulated with tetanus toxoid. Curr. Drug Deliv. 2008, 5(2), 108-113.
129. Naito, T.; Kaneko, Y.; Kozbor, D. Oral vaccination with modified vaccinia virus Ankara attached covalently to TMPEG-modified cationic liposomes overcomes pre-existing poxvirus immunity from recombinant vaccinia immunization. J. Gen. Virol. 2007, 88(1), 61.
130. Mitchell, L. A.; Joseph, A.; Kedar, E.; Barenholz, Y.; Galun, E. Mucosal immunization against hepatitis A: antibody responses are enhanced by co administration of synthetic oligodeoxynucleotides and a novel cationic lipid. Vaccine 2006, 24(25), 5300-5310.
131. Sloat, B. R.; Cui, Z.; Evaluation of the immune response induced by a nasal anthrax vaccine based on the protective antigen protein in anaesthetized and non-anaesthetized mice. J. Pharm. Pharmacol. 2006, 58(4), 439.
132. de Jonge, M. I.; Hamstra, H. J.; Jiskoot, W.; Roholl, P.; Williams, N. A.; Dankert, J.; Alphen, L.; van der Ley, P. Intranasal immunisation of mice with liposomes containing recombinant meningococcal OpaB and OpaJ proteins. Vaccine 2004, 22(29-30), 4021-4028.
133. Wang, D.; Christopher, M. E.; Nagata, L. P.; Zabielski, M. A.; Li, H.; Wong, J. P.; Samuel, J.; Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses. J. Clin. Virol. 2004, 31, 99-106.
134. Leelawongtawon, R.; Somroop, S.; Chaisri, U.; Tongtawe, P.; Chongsanguan, M.; Kalambaheti, T.; Tapchaisri, P.; Pichyangkul, S.; Sakolvaree, Y.; Kurazono, H.; CpG DNA, liposome and refined antigen oral cholera vaccine. Asian Pac. J. Allergy Immunol. 2003, 21(4), 231.
135. Hall, M. A.; Stroop, S. D.; Hu, M. C.; Walls, M. A.; Reddish, M. A.; Burt, D. S.; Lowell, G. H.; Dale, J. B.; Intranasal immunization with multivalent group a streptococcal vaccines protects mice against intranasal challenge infections. Infect. Immun. 2004, 72(5), 2507-2512.
136. Watarai, S.; Isogai, E.; Oguma, K.; Induction of intestinal IgA and IgG antibodies preventing adhesion of verotoxin-producing Escherichia coli to Caco 2 cells by oral immunization with liposomes. Lett. Appl. Microbiol. 2003, 36(3), 135-139.
137. Hasegawa, A.; Fu, Y.; Koyama, K. Nasal immunization with diphtheria toxoid conjugated-CD52 core peptide induced specific antibody production in genital tract of female mice. Am. J. Reprod. Immunol. 2002, 48(5), 305-311.
138. Venkatesan, N.; Vyas, S. P.; Polysaccharide coated liposomes for oral immunization - evelopment and characterization. Int. J. Pharm. 2000, 203(1-2), 169-177.
139. Brewer, J. M.; Alexander, J. The adjuvant activity of non-ionic surfactant vesicles (niosomes) on the BALB/c humoral response to bovine serum albumin. Immunology 1992, 75(4), 570.
140. Walker, W.; Brewer, J. M.; Alexander, J. Lipid vesicle-entrapped influenza a antigen modulates the influenza a-specific human antibody response in immune reconstituted scid-human mice. Eur. J. Immunol. 1996, 26(7), 1664-1667.
141. Rentel, C. O.; Bouwstra, J. A.; Naisbett, B.; Junginger, H. E. Niosomes as a novel peroral vaccine delivery system. Int. J. Pharm. 1999, 186(2), 161-167.
142. Jain, S.; Singh, P.; Mishra, V.; Vyas, S. P. Mannosylated niosomes as adjuvant-carrier system for oral genetic immunization against Hepatitis B. Immunol. Lett. 2005, 101(1), 41-49.
143. Jain, S.; Vyas, S. P. Mannosylated niosomes as adjuvant-carrier system for oral mucosal immunization. J. Liposome Res. 2006, 16(4), 331-345.
144. Katare, R.; Gupta, P. N.; Mahor, S.; Rawat, A.; Khatri, K.; Katare, Y.; Panda, A. K.; Vyas, S. P.; Arimoto, M.; Fukumori, Y. Development of poly saccharide-capped niosomes for oral immunization of tetanus toxoid. J. Drug Deliv. Sci. Technol. 2006, 16(3), 167-172.
145. Mann, J. F. S.; Ferro, V. A.; Mullen, A. B.; Tetley, L.; Mullen, M.; Carter, K. C.; Alexander, J.; Stimson, W. H. Optimisation of a lipid based oral delivery system containing A/Panama influenza haemagglutinin. Vaccine 2004, 22(19), 2425-2429.
146. Mann, J. F. S.; Scales, H. E.; Shakir, E.; Alexander, J.; Carter, K. C.; Mullen, A. B.; Ferro, V. A. Oral delivery of tetanus toxoid using vesicles containing bile salts (bilosomes) induces significant systemic and mucosal immunity. Methods 2006, 38(2), 90-95.
147. Senior, K. Bilosomes: the answer to oral vaccine delivery? Drug Discov. Today 2001, 6(20), 1031-1032.
148. Conacher, M.; Alexander, J.; Brewer, J. M. Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes). Vaccine 2001, 19(20-22), 2965-2974.
149. Singh, P.; Prabakaran, D.; Jain, S.; Mishra, V.; Jaganathan, K. S.; Vyas, S. P. Cholera toxin B subunit conjugated bile salt stabilized vesicles (bilosomes) for oral immunization. Int. J. Pharm. 2004, 278(2), 379-390.
150. Shukla, A.; Khatri, K.; Gupta, P. N.; Goyal, A. K.; Mehta, A.; Vyas, S. P. Oral immunization against hepatitis B using bile salt stabilized vesicles (bilosomes). J. Pharm. Pharm. Sci. 2008, 11(1), 59-63.
151. Mann, J. F. S.; Shakir, E.; Carter, K. C.; Mullen, A. B.; Alexander, J.; Ferro, V. A. Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection. Vaccine 2009, 27(27), 3643-3649.
152. Almeida, J. D.; Edwards, D. C.; Brand, C. M.; Heath, T. D. Formation of virosomes from influenza subunits and liposomes. Lancet 1975, 306, (7941), 899-901.
153. Schaad, U. B.; Buhlmann, U.; Burger, R.; Ruedeberg, A.; Wilder-Smith, A.; Rutishauser, M.; Sennhauser, F.; Herzog, C.; Zellmeyer, M.; Gluck, R. Comparison of immunogenicity and safety of a virosome influenza vaccine with those of a subunit influenza vaccine in pediatric patients with cystic fibrosis. Antimicrob. Agents Chemother. 2000, 44(5), 1163-1167.
154. Durrer, P.; Glück, U.; Spyr, C.; Lang, A. B.; Zurbriggen, R.; Herzog, C.; Glück, R. Mucosal antibody response induced with a nasal virosome-based influenza vaccine. Vaccine 2003, 21(27-30), 4328-4334.
155. Huckriede, A.; Bungener, L.; Stegmann, T.; Daemen, T.; Medema, J.; Palache, A. M.; Wilschut, J. The virosome concept for influenza vaccines. Vaccine 2005, 23(Supplement 1), S26-S38.
156. Dagan, R.; Amir, J.; Livni, G.; Greenberg, D.; Abu-Abed, J.; Guy, L.; Ashkenazi, S.; Froesner, G.; Tewald, F.; Schaetzl, H. M. Concomitant administration of a virosome-adjuvanted hepatitis a vaccine with routine childhood vaccines at age twelve to fifteen months: a randomized controlled trial. Pediatr. Infect. Dis. J. 2007, 26(9), 787.
157. Radosevic, K.; Rodriguez, A.; Mintardjo, R.; Tax, D.; Bengtsson, K. L.; Thompson, C.; Zambon, M.; Weverling, G. J.; UytdeHaag, F.; Goudsmit, J.; Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: Impact of distinct additional adjuvants. Vaccine 2008, 26(29-30), 3640-3646.
158. Felnerova, D.; Viret, J.; Glück, R.; Moser, C. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr. Opin. Biotechnol. 2004, 15(6), 518-529.
159. Cavanagh, D. R.; Remarque, E. J.; Sauerwein, R. W.; Hermsen, C. C.; Luty, A. J. F. Influenza virosomes: a flu jab for malaria? Trends Parasitol. 2008, 24(9), 382-385.
160. Kersten, A. J. L. Gerez, P. J. Schoen, J. P. Nauta, Van, D. H.; Intranasal or inhalational administration of virosomes. U.S. Patent Application 20080038294 Feb 14 2008.
161. Conne, P.; Gauthey, L.; Vernet, P.; Althaus, B.; Que, J. U.; Finkel, B.; Glück, R.; Cryz, S. J. Immunogenicity of trivalent subunit versus virosome formulated influenza vaccines in geriatric patients. Vaccine 1997, 15(15), 1675-1679.
162. Glück, R.; Preclinical and clinical evaluation of a new virosomal intranasal influenza vaccine. Int. Congr. Ser. 2001, 1219, 969-978.
163. Cusi, M. G.; Lomagistro, M. M.; Valassina, M.; Valensin, P. E.; Glück, R. Immunopotentiating of mucosal and systemic antibody responses in mice by intranasal immunization with HLT-combined influenza virosomal vaccine. Vaccine 2000, 18(25), 2838-2842.
164. Freund, J.; Thomson, K. J.; Hough, H. B.; Sommer, H. E.; Pisani, T. M.; Antibody formation and sensitization with the aid of adjuvants. J. Immunol. 1948, 60(3), 383.
165. Muller, R. H.; Mader, K.; Gohla, S. Solid lipid nanoparticles for controlled drug delivery-a review of the state of the art. Eur. J. Pharm. Biopharm. 2000, 50(1), 161-177.
166. Hasbrouck, L.; McNicholl, J. M.; Ruhadze, E.; Bond, K. B.; Hunter, R. L.; Adjuvant enhances proliferative responses to HIV-1SF2 V3 loop peptide. In National Conference on Human Retroviruses and Related Infections, Los Angeles, 1993.
167. Tomasi, M.; Dertzbaugh, M. T.; Hearn, T.; Hunter, R. L.; Elson, C. O. Strong mucosal adjuvanticity of cholera toxin within lipid particles of a new multiple emulsion delivery system for oral immunization. Eur. J. Immunol. 1997, 1997, 2720-5.
168. Myc, A.; Kukowska-Latallo, J. F.; Bielinska, A. U.; Cao, P.; Myc, P. P.; Janczak, K.; Sturm, T. R.; Grabinski, M. S.; Landers, J. J.; Young, K. S.; Chang, J.; Hamouda, T.; Olszewski, M. A.; Baker, J. R. Development of immune response that protects mice from viral pneumonitis after a single in tranasal immunization with influenza A virus and nanoemulsion. Vaccine 2003, 21(25-26), 3801-3814.
169. Baker, J. R.; Shih, A.; Methods of preventing and treating microbial infections. U.S.6506803, Sep 28, 2006.
170. Baker, J. R.; Bielinska, A.; Landers, J.; Janczak, K.; Cao, P.; Enhanced systemic and mucosal immune responses in mice immunized with recombinant Bacillus anthracis protective antigen (rPA) using a novel nanoemulsion adjuvant. J. Allergy Clin. Immunol. 2004, 113(2), 292-292.
171. Ge, W.; Li, Y.; Li, Z. S.; Zhang, S. H.; Sun, Y. J.; Hu, P. Z.; Wang, X. M.; Huang, Y.; Si, S. Y.; Zhang, X. M.; The antitumor immune responses induced by nanoemulsion-encapsulated MAGE1-HSP70/SEA complex protein vaccine following peroral administration route. Cancer Immunol. Immunother. 2009, 58(2), 201-208.
172. [172] Bielinska, A. U.; Janczak, K. W.; Landers, J. J.; Makidon, P.; Sower, L. E.; Peterson, J. W.; Baker Jr, J. R.; Mucosal immunization with a novel nanoe mulsion-based recombinant anthrax protective antigen vaccine protects against bacillus anthracis spore challenge? Infect. Immun. 2007, 75(8), 4020-029.
173. Aulenta, F.; Hayes, W.; Rannard, S. Dendrimers: a new class of nanoscopic containers and delivery devices. Eur. Polym. J. 2003, 39(9), 1741-1771.
174. Boas, U.; Heegaard, P. M. H. Dendrimers in drug research. Chem. Soc. Rev. 2004, 33(1), 43-63.
175. Wright, D. C. Adjuvant properties of poly(amidoamine) dendrimers U.S. Patent 5795582, Aug 18 1998.
176. Belldegrun, A. Tso, C.L. Kidney-specific tumor vaccine directed against kidney tumor antigen G-250. U.S. Patent 2002/0058041 A1, May 16 2002.
177. in het Panhuis, M. Vaccine delivery by carbon nanotubes. Chem. Biol. 2003, 10(10), 897-898.
178. Pantarotto, D.; Partidos, C. D.; Hoebeke, J.; Brown, F.; Kramer, E.; Briand, J. P.; Muller, S.; Prato, M.; Bianco, A. Immunization with Peptide-Functionalized Carbon Nanotubes Enhances Virus-Specific Neutralizing Antibody Responses. Chem. Biol. 2003, 10(10), 961-966.
179. Frehill, F.; Vos, J. G.; Benrezzak, S.; Koos, A. A.; Konya, Z.; Ruther, M. G.; Blau, W. J.; Fonseca, A.; Nagy, J. B.; Biro, L. P.; Minett, A. I.; In Het Panhuis, M.; Interconnecting carbon nanotubes with an inorganic metal complex. J. Am. Chem. Soc. 2002, 124(46), 13694-13695.
180. Pantarotto, D.; Partidos, C. D.; Graff, R.; Hoebeke, J.; Briand, J. P.; Prato, M.; Bianco, A.; Synthesis, structural characterization, and immunological properties of carbon nanotubes functionalized with peptides. J. Am. Chem. Soc. 2003, 125(20), 6160-6164.
181. Sun, Y. P.; Fu, K.; Lin, Y.; Huang, W. Functionalized carbon nanotubes: properties and applications. Acc. Chem. Res. 2002, 35(12), 1096-1104.
182. in het Panhuis, M.; Maiti, A.; Dalton, A. B.; van den Noort, A.; Coleman, J. N.; McCarthy, B.; Blau, W. J. Selective interaction in a polymer-single-wall carbon nanotube composite. J. Phys. Chem. B 2003, 107(2), 478-482.
183. Dieckmann, G. R.; Dalton, A. B.; Johnson, P. A.; Razal, J.; Chen, J.; Giordano, G. M.; Munoz, E.; Musselman, I. H.; Baughman, R. H.; Draper, R. K. Controlled assembly of carbon nanotubes by designed amphiphilic peptide helices. J. Am. Chem. Soc. 2003, 125(7), 1770-1777.
184. Wang, S.; Humphreys, E. S.; Chung, S.-Y.; Delduco, D. F.; Lustig, S. R.; Wang, H.; Parker, K. N.; Rizzo, N. W.; Subramoney, S.; Chiang, Y.-M.; Jagota, A. Peptides with selective affinity for carbon nanotubes. Nat. Mater. 2003, 2(3), 196-200.
185. Pantarotto, D.; Briand, J. P.; Prato, M.; Bianco, A. Translocation of bioactive peptides across cell membranes by carbon nanotubes. Chem. Commun. 2004, 2004(1), 16-17.
186. Kostarelos, K.; Lacerda, L.; Pastorin, G.; Wu, W.; Wieckowski, S.; Luangsivilay, J.; Godefroy, S.; Pantarotto, D.; Briand, J. P.; Muller, S. Cellular uptake of functionalized carbon nanotubes is independent of functional group and cell type. Nat. Nanotechnol. 2007, 2(2), 108-113.
187. Kam, N. W. S.; Dai, H. Carbon nanotubes as intracellular protein transporters: generality and biological functionality. J. Am. Chem. Soc. 2005, 127 (16), 6021-6026.
188. Torchilin, V. P.; Structure and design of polymeric surfactant-based drug delivery systems. J. Control. Release 2001, 73(2-3), 137-172.
189. Scholz, C.; Iijima, M.; Nagasaki, Y.; Kataoka, K. Polymeric micelles as drug delivery systems: a reactive polymeric micelle carrying aldehyde groups. Polym. Adv. Technol. 1998, 9, 768-776.
190. Newman, M. J.; Balusubramanian, M.; Todd, C. W. Development of adjuvant-active nonionic block copolymers. Adv. Drug Deliv. Rev. 1998, 32(3), 199-223.
191. Hao, J.; Kwissa, M.; Pulendran, B.; Murthy, N. Peptide crosslinked micelles: a new strategy for the design and synthesis of peptide vaccines. Int. J. Nanomed. 2006, 1(1), 97-103.
192. Berzofsky, J. A.; Belyakov, I. M.; Derby, M. A.; Kelsall, B. L.; Strober, W. Mucosal cytotoxic T lymphocyte responses. U.S.6749856, Jun 15, 2005